Abstract
AbstractHead and Neck Squamous Cell Carcinoma (HNSCC) is an aggressive epithelial cancer with poor overall response rates to checkpoint inhibitor therapy (CPI) despite CPI being the recommended treatment for recurrent or metastatic HNSCC. Mechanisms of resistance to CPI in HNSCC are poorly understood. To identify drivers of response and resistance to CPI in a unique patient who was believed to have developed three separate HNSCCs, we performed single-cell RNA-seq (scRNA-seq) profiling of two responding lesions and one progressive lesion that developed during CPI. Our results not only suggest interferon-induced APOBEC3-mediated acquired resistance as a mechanism of CPI resistance in the progressing lesion but further, that the lesion in question was actually a metastasis as opposed to a new primary tumor, highlighting the immense power of scRNA-seq as a clinical tool for inferring tumor origin and mechanisms of therapeutic resistance.
Funder
U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research
DLF Sundry Funds
LW Sundry Funds
Publisher
Springer Science and Business Media LLC
Reference52 articles.
1. Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 72, 7–33 (2022).
2. Howlader, N. et al. SEER Cancer Statistics Review, 1975–2018 (National Cancer Institute, 2021).
3. Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2021. CA Cancer J. Clin. 71, 7–33 (2021).
4. Zhang, W. L. et al. Susceptibility of multiple primary cancers in patients with head and neck cancer: nature or nurture? Front Oncol. 9, 1275 (2019).
5. Tabor, M. P. et al. Multiple head and neck tumors frequently originate from a single preneoplastic lesion. Am. J. Pathol. 161, 1051–1060 (2002).